Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2014; 20(23): 7079-7088
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7079
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7079
Emerging therapeutic options for the management of hepatitis C infection
J Richard Thompson, Department of Pharmacy Practice, One University Park Drive, Lipscomb University College of Pharmacy, Nashville, TN 37204, United States
Author contributions: Thompson JR reviewed the literature and wrote the entire content for this manuscript.
Correspondence to: J Richard Thompson, PharmD, MBA, BCPS, Department of Pharmacy Practice, One University Park Drive, Lipscomb University College of Pharmacy, Nashville, TN 37204, United States. richard.thompson@lipscomb.edu
Telephone: +1-615-9667172 Fax: +1-615-9667163
Received: October 10, 2013
Revised: January 22, 2014
Accepted: May 1, 2014
Published online: June 21, 2014
Revised: January 22, 2014
Accepted: May 1, 2014
Published online: June 21, 2014
Core Tip
Core tip: A plethora of new agents for the management of hepatitis C promising higher response rates and better tolerated side effect profiles is upon us. Many of these new drugs in development utilize novel pharmacologic mechanisms and may replace older more toxic therapies such as interferon and ribavirin. In addition, once daily dosing and shorter treatment durations should help improve adherence and optimize therapeutic outcomes for hepatitis C infection.